News
The FDA is spreading lies about medications people need—and starting their attack by targeting pregnant women.
Positive data on depression treatment based on a drug related to the psychedelic DMT is breathing life into shares of biotechs working on psychedelic medicines, after years of disappointments. Just as ...
Members of an FDA expert panel discussed the risks and benefits of selective serotonin reuptake inhibitors, or SSRIs, for ...
Doctors on Monday urged the U.S. Food and Drug Administration to issue warnings to pregnant women against the use of certain ...
The drug, called Zulresso, is only available through 60-hour, one-time infusion, and can cost as much as $20,000 to $35,000 per treatment. Postpartum depression affects as many as 1 in 8 women who ...
Market reaction to recent readouts from Compass Pathways and Beckley Psytech/atai in treatment-resistant depression speaks to ...
Zulresso is the first treatment specifically intended for women with postpartum depression. Administered intravenously, the drug is designed to work faster than other antidepressants. 2.
The FDA approved the pill zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for major depressive disorder.
Zulresso is also the first drug developed by and approved from Sage Therapeutics, a Cambridge, Mass.-based biotech. Postpartum depression disorder, which affects approximately 400,000 women each ...
Hosted on MSN5mon
Supernus’s stock sinks after depression drug fails trial - MSNSupernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an investigational treatment for adults with treatment-resistant depression ...
Compass Pathways' psilocybin-based depression therapy reduced the severity of symptoms in a closely watched study, but shares of the biotech firm plunged more than 46% to a record low on Monday as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results